Investigating the Promising Anticancer Activity of Cetuximab and Fenbendazole Combination as Dual CBS and VEGFR-2 Inhibitors and Endowed with Apoptotic Potential. (2024)

Peer-Reviewed Study · Norhan M Eid; Ahmed A Al-Karmalawy; Taha M A Eldebss et al. · April 2024

Norhan M Eid et al., 2024-04: Eid et al. test fenbendazole, cetuximab and their combination in a colchicine-tubulin binding assay and against VEGFR-2, with docking of fenbendazole into the colchicine binding site.

Ce, Fen, and a combination between them were subjected to a colchicine-tubulin binding test, which was conducted and compared to Colchicine as a reference standard.

Norhan M Eid et al., 2024-04: Eid et al. test fenbendazole, cetuximab and their combination in a colchicine-tubulin binding assay and against VEGFR-2, with docking of fenbendazole into the colchicine binding site. Study type: cell lines plus in vitro binding and enzyme assays and molecular docking. N: not stated in the abstract. Country: Egypt (Cairo University). Dose: not stated in the abstract text captured. Funder: not stated in the record. Declared conflicts: no COI statement in the record. Comparator: colchicine as the reference standard for tubulin binding and sorafenib for VEGFR-2. CAUTION FOR THE VERIFIER: the abstract describes the assays rather than the numeric result, so this row is quoted from the methods paragraph; the paper's position is that fenbendazole competes at the colchicine site. This is the direct evidence for 'binds tubulin like colchicine' rather than like a taxane. Study type: lab.